For research use only. Not for therapeutic Use.
Adenylosuccinic acid tetraammonium (Adenylosuccinate; Aspartyl adenylate) is an orally active purine ribonucleoside monophosphate and plays a role in nucleotide cycle metabolite. Adenylosuccinic acid tetraammonium can be converted into fumaric acid through adenylosuccinate lyase. Adenylosuccinic acid tetraammonium has the potential for the study of duchenne muscular dystrophy(DMD)[1].
Adenylosuccinic acid tetraammonium (oral administration; 3-3000 µg/mL; 6 weeks) significantly improves the features of murine DMD, it decreases the number of centronucleated fibres, lipid accumulation, connective tissue infiltration and Ca2+ content of mdx tibialis anterior[1].
| Catalog Number | I043587 |
| Synonyms | azane;(2S)-2-[[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]purin-6-yl]amino]butanedioic acid |
| Molecular Formula | C14H30N9O11P |
| Purity | ≥95% |
| InChI | InChI=1S/C14H18N5O11P.4H3N/c20-7(21)1-5(14(24)25)18-11-8-12(16-3-15-11)19(4-17-8)13-10(23)9(22)6(30-13)2-29-31(26,27)28;;;;/h3-6,9-10,13,22-23H,1-2H2,(H,20,21)(H,24,25)(H,15,16,18)(H2,26,27,28);4*1H3/t5-,6+,9+,10+,13+;;;;/m0..../s1 |
| InChIKey | XCLZBEXZAOLWGA-BFHDGDRYSA-N |
| SMILES | C1=NC(=C2C(=N1)N(C=N2)C3C(C(C(O3)COP(=O)(O)O)O)O)NC(CC(=O)O)C(=O)O.N.N.N.N |
| Reference | [1]. Timpani CA, et al. Adenylosuccinic acid tetraammonium therapy ameliorates murine Duchenne Muscular Dystrophy.Sci Rep. 2020 Jan 24;10(1):1125. |
